Search results
Eternal Asia Ptd Ltd is one of the leading distribution companies in the Asia Pacific Region as we expand our business globally. We distributes a variety of products which includes External & Internal Storage Devices, Flash Memory, SSD, LCD Display, Networking, NAS Data Storage and UPS.
Founded in 1997, Shenzhen Eternal Asia Supply Chain Management Co., Ltd. is a subsidiary of Shenzhen Investment Holding Co., Ltd., one of the World's Top 500 Companies; it is the first A-share supply chain enterprise in China (Stock Code: 002183).
Eternal Asia Distribution (S) Pte Ltd 23 Serangoon North Avenue 5 BTC Centre #06-02 554530 Singapore Singapore
Eternal Asia Distribution (S) Pte Ltd 23 Serangoon North Avenue 5 BTC Centre #06-02 554530 Singapore Singapore
Eternal Asia Distribution (S) Pte Ltd is majority owned by Eternal Asia Supply Chain Management LTD, a listed corporation in Shenzhen stock exchange since 2007 (Stock Code: 002183) with an estimated market capitalization of U$1 billion. In South East Asia, Eternal Asia focuses on IT distribution and is headquartered in Singapore.
Eternal Asia was listed on the Shenzhen A-share market, becoming the first supply chain company in China to go public. Vice Mayor Zhang Siping and President Zhou Guohui attended the 10th anniversary ceremony of Eternal Asia.
深圳市怡亚通供应链股份有限公司成立于1997年，是世界500强——深圳市投资控股有限公司旗下企业，中国首家上市供应链公司（股票代码002183），是以“供应链+产业链+孵化器”模式，打造集供应链平台服务、产业链整合运营、品牌营销、数字化商业、企业投融 ...
Jul 28, 2016 · Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial.
Contact us. We wholeheartedly provide you with the following services. Business Consultation: Provide consultation and promotion services for the company's business and products, as well as guidance on services provided before, during, and after sales.
Nov 25, 2020 · Preclinical studies support the efficacy of expanded allogeneic adipose-derived mesenchymal stem cells (eASCs) in the treatment of sepsis. In this study, we aim to test the safety, tolerability and efficacy of eASCs as adjunctive therapy in patients with severe CABP (sCABP).
